Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Pembrolizumab Plus Chemotherapy and Bevacizumab vs Placebo in Patients With Cervical Cancer
11/07/2022
Did patients with cervical cancer experience prolonged PFS and OS when treated with pembrolizumab plus chemotherapy and bevacizumab compared to patients treated with placebo?
Did patients with cervical cancer experience prolonged PFS and OS when treated with pembrolizumab plus chemotherapy and bevacizumab compared to patients treated with placebo?
Did patients with cervical...
11/07/2022
Oncology
Test Your Knowledge
Quiz: Is LGSOC Generally Resistant to Chemotherapy?
08/27/2021
True or false: LGSOC comprises 6% to 8% of all ovarian cancers and generally resists chemotherapy with a median survival of approximately 10 years.
True or false: LGSOC comprises 6% to 8% of all ovarian cancers and generally resists chemotherapy with a median survival of approximately 10 years.
True or false: LGSOC comprises...
08/27/2021
Oncology
Test Your Knowledge
Quiz: Is LGSOC Generally Resistant to Chemotherapy?
08/27/2021
True or false: LGSOC comprises 6% to 8% of all ovarian cancers and generally resists chemotherapy with a median survival of approximately 10 years.
True or false: LGSOC comprises 6% to 8% of all ovarian cancers and generally resists chemotherapy with a median survival of approximately 10 years.
True or false: LGSOC comprises...
08/27/2021
Oncology
doc
Test Your Knowledge
Quiz: Upfront MGPT vs Tumor Screening for Lynch Syndrome in Endometrial Cancer
06/02/2021
True or False: Upfront multi-gene panel testing in patients with endometrial cancer has been shown to detect cases of Lynch syndrome not identified by tumor screening.
True or False: Upfront multi-gene panel testing in patients with endometrial cancer has been shown to detect cases of Lynch syndrome not identified by tumor screening.
True or False: Upfront...
06/02/2021
Oncology
Test Your Knowledge
Quiz: A Common Thread in Rising Endometrial Cases in US Women
05/29/2021
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in...
05/29/2021
Oncology
Test Your Knowledge
Quiz: Is Upfront Germline Genetic Testing Encouraged in Endometrial Cancer?
05/28/2021
True or False: Experts opine that upfront germline genetic testing should be considered for patients with any and all solid tumors, including endometrial cancer.
True or False: Experts opine that upfront germline genetic testing should be considered for patients with any and all solid tumors, including endometrial cancer.
True or False: Experts opine...
05/28/2021
Oncology
Test Your Knowledge
Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?
05/28/2021
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings...
05/28/2021
Oncology
Test Your Knowledge
Quiz: Which Therapy Extended PFS for Ovarian Cancer in the ARIEL3 Study?
10/08/2020
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
According to the ARIEL3 study,...
10/08/2020
Oncology
Test Your Knowledge
Quiz: Does Pembrolizumab Yield Promising Results in Advanced Urothelial Cancer?
09/10/2020
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Pembrolizumab...
09/10/2020
Oncology
Test Your Knowledge
Quiz: Long-Term Maintenance Olaparib for BRCA-Mutated, Relapsed Ovarian Cancer?
06/25/2020
True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.
True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.
True or false: Maintenance...
06/25/2020
Oncology

Recent News

News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology
News
Ropeginterferon Shows Efficacy Across Treatment Lines and Mutation Subtypes in Essential Thrombocythemia
06/01/2026
Stephanie Holland
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated...
06/01/2026
Oncology
News
Asandeutertinib Demonstrates Superior Intracranial Efficacy in EGFR-Mutated NSCLC
05/31/2026
Emily Estrada
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA...
05/31/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
HARMONi-6 Trial Positions Ivonescimab Plus Chemotherapy as New First-Line Standard of Care in Squamous NSCLC
05/31/2026
Emily Estrada
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial...
05/31/2026
Oncology
News
Metronomic Chemo-Immunotherapy Improves Survival in Metastatic Head and Neck Cancer
05/31/2026
Stephanie Holland
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial...
05/31/2026
Oncology
News
Adding Sintilimab to Adjuvant Capecitabine Fails to Improve PFS in High-Risk Nasopharyngeal Carcinoma
05/31/2026
Stephanie Holland
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase...
05/31/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Omitting Axillary Lymph Node Dissection Appears Safe in Node-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC...
05/30/2026
Oncology
News
Anbenitamab Demonstrates Significant Neoadjuvant Benefit in HER2-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial...
05/30/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use